Literature DB >> 17079239

Are laboratory-based antibiograms reliable to guide the selection of empirical antimicrobial treatment in patients with hospital-acquired infections?

Carlos Bantar1, Gabriela Alcazar, Diego Franco, Francisco Salamone, Eduardo Vesco, Teodoro Stieben, Florencia Obaid, Alejandro Fiorillo, Mariano Izaguirre, María Eugenia Oliva.   

Abstract

OBJECTIVES: Antibiograms are often taken into account to define a rational selection of an empirical antimicrobial therapy for treating patients with hospital-acquired infections. In this study, we performed a paired comparison between the antibiogram constructed with laboratory-based data and that formed with data subjected to prior clinical validation.
METHODS: Between 2003 and 2005, the laboratory of microbiology printed in duplicate every individual susceptibility report corresponding to hospitalized patients and the copy was sent to the department of infection control. Every individual report was assessed in real time at the bedside of the patient by a multidisciplinary team for clinical significance and appropriateness of the specimen, as well as for the type, source and origin of the infection. Cumulative resistance rates were estimated in parallel at the laboratory with the whole data, and at the infection control department with data subjected to prior clinical validation. These rates were designated as 'laboratory-based' and 'clinically based', respectively.
RESULTS: A total of 2305 individual susceptibility reports were assessed. Only 1429 (62.0%) were considered as clinically significant by the multidisciplinary team. Escherichia coli, Enterobacter cloacae, Citrobacter freundii group, Klebsiella species and Proteus mirabilis resistant to broad-spectrum cephalosporins, as well as methicillin-resistant Staphylococcus aureus, were significantly more frequent in the clinically based rates (P < or = 0.03).
CONCLUSIONS: Laboratory-based data underestimate the frequency of several major resistant organisms in patients with hospital-acquired infection. Previous clinical validation of the individual susceptibility reports seems to be a suitable strategy to get more reliable data.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17079239     DOI: 10.1093/jac/dkl434

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  6 in total

1.  Systematic review of antibiograms: A National Laboratory System approach for improving antimicrobial susceptibility testing practices in Michigan.

Authors:  Martha S Boehme; Patricia A Somsel; Frances Pouch Downes
Journal:  Public Health Rep       Date:  2010 May-Jun       Impact factor: 2.792

Review 2.  Antimicrobial stewardship programs.

Authors:  Kimberly D Leuthner; Gary V Doern
Journal:  J Clin Microbiol       Date:  2013-08-07       Impact factor: 5.948

3.  Strengthening Public Health in Wisconsin Through the Wisconsin Clinical Laboratory Network.

Authors:  Allen C Bateman; Erin J Bowles; Erik Munson; Raymond P Podzorski; Eric T Beck; Richard Dern; Alana K Sterkel; David M Warshauer; Peter A Shult
Journal:  Public Health Rep       Date:  2019 Nov/Dec       Impact factor: 2.792

4.  Ability of an antibiogram to predict Pseudomonas aeruginosa susceptibility to targeted antimicrobials based on hospital day of isolation.

Authors:  Deverick J Anderson; Becky Miller; Ruchit Marfatia; Richard Drew
Journal:  Infect Control Hosp Epidemiol       Date:  2012-04-13       Impact factor: 3.254

5.  Comparison of Hospitalwide and Custom Antibiograms for Clinical Isolates of Pseudomonas aeruginosa.

Authors:  John A Bosso; Adam Sieg; Patrick D Mauldin
Journal:  Hosp Pharm       Date:  2013-04

6.  Evaluation of Immunocompetent Urinary Tract Infected Balb/C Mouse Model For the Study of Antibiotic Resistance Development Using Escherichia Coli CFT073 Infection.

Authors:  Ashok Chockalingam; Sharron Stewart; Lin Xu; Adarsh Gandhi; Murali K Matta; Vikram Patel; Leonard Sacks; Rodney Rouse
Journal:  Antibiotics (Basel)       Date:  2019-09-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.